Citations

Clear

6273 citation(s) found for "To, Andrew".

Microsurgical Treatment of Intracranial Dural Arteriovenous Fistulas: A Collaborative Investigation From the Multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research
Raygor, Kunal P. , Abdelsalam, Ahmed , Raper, Daniel , Guniganti, Ridhima , Durnford, Andrew , Brinjikji, Waleed , Abecassis, Isaac Josh, Polifka, Adam , Samaniego, Edgar A. , Kwasnicki, Amanda , Potgieser, Adriaan R. E., Tada, Yoshiteru , Kansagra, Akash P. , Satomi, Junichiro, Eatz, Tiffany , Peterson, Eric C. , Starke, Robert M., Dijk, J. Marc C. van , Hayakawa, M. , Gross, Bradley A. , Fox, W. Christopher, Kim, Louis J. , Sheehan, Jason , Bulters, Diederik , Zipfel, Gregory J. , Abla, Adib A. , Alaraj, Ali , Eatz, Tiffany , Alaraj, Ali , Samaniego, Edgar A , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Tonetti, Daniel A. , Giordan, Enrico , Chen, Ching‐Jen , Levitt, Michael R. , Derdeyn, Colin P. , Chen, Stephanie , Peterson, Eric C., Amin-Hanjani, Sepideh , Gross, Bradley , Fox, W Christopher , Kim, Louis J. , Lanzino, Giuseppe , Du, Rose , Lai, Pui Man Rosalind

Mayo Clinic

Neurosurgery | October 8, 2024 | Volume: 96 | Issue: 5 | Pages: 1023-1034

10.1227/neu.0000000000003204 | PMID 39471093 Get It

BACKGROUND AND OBJECTIVES: First-line therapy for most intracranial dural arteriovenous fistulas (dAVFs) is endovascular embolization, but some require microsurgical ligation due to limited endovascular accessibility, anticipated lower cure rates, or unacceptable risk profiles. We investigated the most common surgically treated dAVF locations and the approaches and outcomes of each. METHODS: The Consortium for Dural Arteriovenous Fistula Outcomes Research database was retrospectively reviewed. Patients who underwent dAVF microsurgical ligation were included. Patient demographics, angiographic information, surgical details, and postoperative outcomes were collected. The 5 most common surgically treated dAVF locations were analyzed about used surgical approaches and postoperative outcomes. Univariate analyses were performed with statistical significance set at a threshold of P < .05. RESULTS: In total, 248 patients in the Consortium for Dural Arteriovenous Fistula Outcomes Research database met inclusion criteria. The 5 most common surgically treated dAVF locations were tentorial, anterior cranial fossa (ACF), transverse-sigmoid sinus (TSS), convexity/superior sagittal sinus (SSS), and torcular. Most tentorial dAVFs were approached using a suboccipital, lateral supracerebellar infratentorial approach (39.3%); extended retrosigmoid approach (ERS) (25%); or posterior subtemporal approach (19.6%). All ACF dAVFs used a subfrontal approach; 5.3% also included an anterior interhemispheric approach. Most TSS dAVFs were ligated via ERS (31.3%) or subtemporal (31.3%) approaches. All convexity/SSS dAVFs used an interhemispheric approach. All torcular dAVFs used the suboccipital, lateral supracerebellar infratentorial approach, with 10.5% undergoing simultaneous ERS craniotomy. Angiographic occlusion rates after microsurgery were 85.5%, 100%, 75.8%, 79.2%, and 73.7% for tentorial, ACF, TSS, convexity/SSS, and torcular dAVFs, respectively ( P = .02); the permanent neurological complication rates were 1.8%, 2.6%, 9.1%, 0%, and 0% ( P = .31). There were no statistically significant differences in development of complications ( P = .08) or Modified Rankin Scale at the last follow-up ( P = .11) by fistula location. CONCLUSION: Although endovascular embolization is the first-line treatment for most intracranial dAVFs, surgical ligation is an important alternative. ACF and tentorial fistulas particularly demonstrate high rates of postoperative obliteration.
How I treat blastic plasmacytoid dendritic cell neoplasm
Kharfan‐Dabaja, Mohamed A. , Lane, Andrew A. , Pemmaraju, Naveen , Lane, Andrew A

Mayo Clinic

Blood | October 7, 2024 | Volume: 145 | Issue: 6 | Pages: 567-576

10.1182/blood.2024024262 | PMID 39374520 Get It

Abstract Historically, treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN) were limited to conventional chemotherapy, adopted from regimens used to treat acute myeloid or acute lymphoblastic leukemias, or lymphomas. Nowadays, a novel therapy targeting CD123 is available to treat BPDCN. Yet, regardless of treatment choice, achieving a first complete remission represents the main goal of therapy, because it represents the best opportunity to prolong survival in BPDCN, if offered an allogeneic hematopoietic cell transplant (allo-HCT) as consolidative therapy. Although no specific conditioning regimen is considered standard of care in allo-HCT–eligible patients, recent data from 2 large registries reported a survival advantage when offering total body irradiation–based myeloablative conditioning (MAC) regimens. Unfortunately, applicability of MAC regimens is not feasible in patients who are older/unfit, which represents a considerable proportion of patients presenting worldwide. In such cases, reduced intensity conditioning regimens represent the next best option. Autologous HCT could be considered in patients who are older/unfit who did not have bone marrow involvement at initial presentation and at time of the procedure, albeit data supporting this option are less abundant. Future research is needed to decipher the interplay between clinical, genetic, and molecular features of the disease to personalize treatment accordingly, by enhancing efficacy and avoiding unnecessary toxicities.
Non-rapid eye movement sleep slow-wave activity features are associated with amyloid accumulation in older adults with obstructive sleep apnoea
Carvalho, Diego Z. , Křemen, Václav , Mívalt, Filip , Louis, Erik K. St. , Bukartyk, Jan , Przybelski, Scott A. , Kamykowski, Michael G. , Spychalla, Anthony J., Petersen, Ronald , Jack, Clifford R. , Lowe, Val J. , Graff‐Radford, Jonathan , Somers, Virend K. , Varga, Andrew W. , St Louis, E K , Boeve, Brad , Jack, Clifford R , Graff-Radford, Jonathan , Varga, Andrew W , Vemuri, Prashanthi , Kremen, Vaclav , Carvalho, Diego Z , Mivalt, Filip , McCarter, Stuart J. , Machulda, Mary M. , Boeve, Bradley F. , Worrell, Gregory A. , Somers, Virend K. , Vemuri, Prashanthi

Mayo Clinic

Brain Communications | October 7, 2024 | Volume: 6 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcae354 | PMID 39429245 Get It

Abstract Obstructive sleep apnoea (OSA) is associated with an increased risk for cognitive impairment and dementia, which likely involves Alzheimer’s disease pathology. Non-rapid eye movement slow-wave activity (SWA) has been implicated in amyloid clearance, but it has not been studied in the context of longitudinal amyloid accumulation in OSA. This longitudinal retrospective study aims to investigate the relationship between polysomnographic and electrophysiological SWA features and amyloid accumulation. From the Mayo Clinic Study of Aging cohort, we identified 71 participants ≥60 years old with OSA (mean baseline age = 72.9 ± 7.5 years, 60.6% male, 93% cognitively unimpaired) who had at least 2 consecutive Amyloid Pittsburgh Compound B (PiB)-PET scans and a polysomnographic study within 5 years of the baseline scan and before the second scan. Annualized PiB-PET accumulation [global ΔPiB(log)/year] was estimated by the difference between the second and first log-transformed global PiB-PET uptake estimations divided by the interval between scans (years). Sixty-four participants were included in SWA analysis. SWA was characterized by the mean relative spectral power density (%) in slow oscillation (SO: 0.5–0.9 Hz) and delta (1–3.9 Hz) frequency bands and by their downslopes (SO-slope and delta-slope, respectively) during the diagnostic portion of polysomnography. We fit linear regression models to test for associations among global ΔPiB(log)/year, SWA features (mean SO% and delta% or mean SO-slope and delta-slope), and OSA severity markers, after adjusting for age at baseline PiB-PET, APOE ɛ4 and baseline amyloid positivity. For 1 SD increase in SO% and SO-slope, global ΔPiB(log)/year increased by 0.0033 (95% CI: 0.0001; 0.0064, P = 0.042) and 0.0069 (95% CI: 0.0009; 0.0129, P = 0.026), which were comparable to 32% and 59% of the effect size associated with baseline amyloid positivity, respectively. Delta-slope was associated with a reduction in global ΔPiB(log)/year by −0.0082 (95% CI: −0.0143; −0.0021, P = 0.009). Sleep apnoea severity was not associated with amyloid accumulation. Regional associations were stronger in the pre-frontal region. Both slow-wave slopes had more significant and widespread regional associations. Annualized PiB-PET accumulation was positively associated with SO and SO-slope, which may reflect altered sleep homeostasis due to increased homeostatic pressure in the setting of unmet sleep needs, increased synaptic strength, and/or hyper-excitability in OSA. Delta-slope was inversely associated with PiB-PET accumulation, suggesting it may represent residual physiological activity. Further investigation of SWA dynamics in the presence of sleep disorders before and after treatment is necessary for understanding the relationship between amyloid accumulation and SWA physiology.
7206 Perioperative Management of Pheochromocytoma: The Mayo Clinic Florida Experience
Elli, Fabrizia , Shapiro, Andrew J. , Moshe, Christine , Verma, A, Elli, F, RAO, S, Smith, Mark M. , Chadha, Ryan

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.257 Get It

Abstract Disclosure: A. Verma: None. F. Elli: None. S. Rao: None. M. Smith: None. A. Shapiro: None. C. Moshe: None. R. Chadha: None. Introduction: Pheochromocytomas are rare, neuroendocrine tumors derived from chromaffin cells of the neural crest, typically within the adrenal medulla. The pathophysiologic effect of primary concern is the uncontrolled release of catecholamines into the bloodstream, which carry risk for episodic hypertension, palpitations, and life-threatening crises. Preoperative preparation with drugs that block adrenergic receptors is utilized to improve hemodynamic oscillation force and surgical outcomes. Widely used premedication include alpha-blockers, beta-blockers, and calcium channel blockers. Despite adequate pretreatment, hemodynamic instability continues to evoke massive risk. The objective of this study was to assess the incidence of intraoperative hypertensive episodes in patients undergoing robotic assisted laparoscopic adrenalectomy. Methods: This study is an observational retrospective analysis of patients who underwent elective laparoscopic robotic-assisted adrenalectomies from February 2019 to April 2023. 17 patients total patients were included. Preoperative information included age, BMI, ASA physical classification, preoperative blockade regiment, and urine metanephrines. Intraoperative information included operation duration, tumor size, intraoperative anti-hypertensives, and hypertensive spikes defined as a SBP greater than 175 mmHg for 5 consecutive minutes. Data analysis was performed to obtain frequency counts (%), means (standard deviations), and median (range) as appropriate. Results: The mean age at the time of surgery was 57.12 ± 17.2 years. The majority of patients (76%) were ASA status class III. 7 of the 17 patients did not have active pheochromocytoma based on symptomatology, the incidental diagnoses being made by imaging and workup. The average tumor diameter was 3.90 ± 1.8, with a range of 2.0 - 8.0. Mean operative time was 153.76 ± 53.9 minutes. Preoperative urinary metanephrines were observed to have a mean of 1,248.44 ± 2,866.9 pg/mL. In terms of preoperative preparation, 65% of patients received Doxazosin, and 29% of patients received an alternative anti-hypertensive. Yet, 64.7% of patients were found to have at least 1 intraoperative hypertensive spike Conclusion: Despite premedication with anti-hypertensives, a significant percentage of patients experienced intraoperative hemodynamic instability. This emphasizes the importance of anesthesiologist preparation for intraoperative hypertension management to aggressively prevent hypertensive crises. In addition, it questions the routine use of alpha blockade for all cases preoperatively as has been suggested in certain studies, and whether or not it should be driven by other patient characteristics. Presentation: 6/1/2024
Telestroke Training: Considerations for Expansion of Vascular Neurology Program Requirements
Guzik, Amy , Jagolino‐Cole, Amanda , Sells, Christina Mijalski , Southerland, Andrew M. , Dumitrascu, Oana M. , Martini, Sharyl , Meyer, Brett C. , Guzik, Amy K , Jagolino-Cole, Amanda L , Mijalski Sells, Christina , Sreekrishnan, Anirudh , Martini, Sharyl R , Meyer, Brett C , Southerland, Andrew M

Mayo Clinic

Stroke | October 2, 2024 | Volume: 56 | Issue: 1 | Pages: 209-218

10.1161/strokeaha.124.047826 | PMID 39355905 Get It

Telemedicine for stroke (Telestroke) has been a key component to efficient, widespread acute stroke care for many years. The expansion of reimbursement through the Furthering Access to Stroke Telemedicine Act and rapid deployment of telemedicine resources during the COVID-19 public health emergency have further expanded remote care, with practitioners of varying educational backgrounds, and experience providing acute stroke care via telemedicine (Telestroke). Some Telestroke practitioners have not had fellowship-level vascular neurology training and many are without training specific to virtual modalities. While many vascular neurology fellowship programs incorporate Telestroke training into the curriculum, components of this curriculum are not consistent, extent of involvement is variable, and not all fellows receive hands-on training in remote care. Furthermore, the extent of training and evaluation of Telestroke in American Board of Psychiatry and Neurology training requirements and Accreditation Council for Graduate Medical Education assessments for vascular neurology fellowship are not standardized. We suggest that Telestroke be formally incorporated into vascular neurology fellowship curricula and provide considerations for key components of this training and metrics for evaluation.
An Eternal Dilemma: Exposing the Impact of Immortal Time Bias on Antifibrotic Effectiveness
Kyle, Andrew R., Dempsey, Timothy , Dempsey, Timothy M

Mayo Clinic

Annals of the American Thoracic Society | October 1, 2024 | Volume: 21 | Issue: 10 | Pages: 1383-1384

10.1513/annalsats.202407-717ed | PMID 39352177 Get It

Association of Hepatorenal Syndrome-Acute Kidney Injury with Mortality in Patients with Cirrhosis Requiring Renal Replacement Therapy
Cama-Olivares, Augusto , Ouyang, Tianqi , Takeuchi, Tomonori , Hillien, Shelsea A. St., Robinson, Jevon E. , Cullaro, Giuseppe , Karvellas, Constantine , Levitsky, Josh , Orman, Eric S. , Patidar, Kavish R. , Regner, Kevin R. , Saly, Danielle L. , Teixeira, J. Pedro , Velez, Juan Carlos Q. , Wahid, Nabeel , Allegretti, Andrew S. , Neyra, Javier A. , Belcher, Justin M. , Cullaro, Giuseppe , Karvellas, Constantine , Orman, Eric S , Sawinski, Deirdre , Teixeira, J Pedro , Ufere, Nneka N , Velez, Juan Carlos Q , Wadei, Hani M , Wahid, Nabeel , Neyra, Javier A , Belcher, Justin M , Patidar, Kavish R , Chung, Raymond T. , Sharma, Pratima , Wadei, Hani M.

Mayo Clinic

Kidney360 | September 30, 2024 | Volume: 6 | Issue: 2 | Pages: 247-256

10.34067/kid.0000000589 | PMID 39348201 Get It

Key Points In patients with cirrhosis and AKI requiring renal replacement therapy (RRT), hepatorenal syndrome-AKI was not associated with an increased 90-day mortality when compared with other AKI etiologies. Etiology of AKI may not be a critical factor regarding decisions to trial RRT in acutely ill patients with cirrhosis and AKI. Although elevated, mortality rates in this study are comparable with those reported in general hospitalized patients with AKI requiring RRT. Background While AKI requiring renal replacement therapy (AKI-RRT) is associated with increased mortality in heterogeneous inpatient populations, the epidemiology of AKI-RRT in hospitalized patients with cirrhosis is not fully known. Herein, we evaluated the association of etiology of AKI with mortality in hospitalized patients with cirrhosis and AKI-RRT in a multicentric contemporary cohort. Methods This is a multicenter retrospective cohort study using data from the HRS-HARMONY consortium, which included 11 US hospital network systems. Consecutive adult patients admitted in 2019 with cirrhosis and AKI-RRT were included. The primary outcome was 90-day mortality, and the main independent variable was AKI etiology, classified as hepatorenal syndrome (HRS-AKI) versus other (non–HRS-AKI). AKI etiology was determined by at least two independent adjudicators. We performed Fine and Gray subdistribution hazard analyses adjusting for relevant clinical variables. Results Of 2063 hospitalized patients with cirrhosis and AKI, 374 (18.1%) had AKI-RRT. Among them, 65 (17.4%) had HRS-AKI and 309 (82.6%) had non–HRS-AKI, which included acute tubular necrosis in most cases (62.6%). Continuous renal replacement therapy was used as the initial modality in 264 (71%) of patients, while intermittent hemodialysis was used in 108 (29%). The HRS-AKI (versus non–HRS-AKI) group received more vasoconstrictors for HRS management (81.5% versus 67.9%), whereas the non–HRS-AKI group received more mechanical ventilation (64.3% versus 50.8%) and more continuous renal replacement therapy (versus intermittent hemodialysis) as the initial RRT modality (73.9% versus 56.9%). In the adjusted model, HRS-AKI (versus non–HRS-AKI) was not independently associated with increased 90-day mortality (subdistribution hazard ratio, 1.36; 95% confidence interval, 0.95 to 1.94). Conclusions In this multicenter contemporary cohort of hospitalized adult patients with cirrhosis and AKI-RRT, HRS-AKI was not independently associated with an increased risk of 90-day mortality when compared with other AKI etiologies. The etiology of AKI appears less relevant than previously considered when evaluating the prognosis of hospitalized adult patients with cirrhosis and AKI requiring RRT.
Fueling the Firefighter and Tactical Athlete with Creatine: A Narrative Review of a Key Nutrient for Public Safety
Gonzalez, Drew E. , Forbes, Scott C. , Zapp, Annette , Jagim, Andrew R. , Luedke, Joel, Root, Alexandria, Gil, Adriana , Johnson, Sarah E. , Coles, Macilynn E., Brager, Allison J. , Sowinski, Ryan , Candow, Darren G. , Kreider, Richard B. , Jagim, Andrew R , Sowinski, Ryan J , Kreider, Richard B , Forbes, Scott C , Dickerson, Broderick L.

Mayo Clinic

Nutrients | September 30, 2024 | Volume: 16 | Issue: 19 | Pages: 3285

10.3390/nu16193285 | PMID 39408252 Get It

Background/Objectives: Firefighters, tactical police officers, and warriors often engage in periodic, intermittent, high-intensity physical work in austere environmental conditions and have a heightened risk of premature mortality. In addition, tough decision-making challenges, routine sleep deprivation, and trauma exacerbate this risk. Therefore, identifying strategies to bolster these personnel’s health and occupational performance is critical. Creatine monohydrate (CrM) supplementation may offer several benefits to firefighters and tactical athletes (e.g., police, security, and soldiers) due to its efficacy regarding physical performance, muscle, cardiovascular health, mental health, and cognitive performance. Methods: We conducted a narrative review of the literature with a focus on the benefits and application of creatine monohydrate among firefighters. Results: Recent evidence demonstrates that CrM can improve anaerobic exercise capacity and muscular fitness performance outcomes and aid in thermoregulation, decision-making, sleep, recovery from traumatic brain injuries (TBIs), and mental health. Emerging evidence also suggests that CrM may confer an antioxidant/anti-inflammatory effect, which may be particularly important for firefighters and those performing tactical occupations exposed to oxidative and physiological stress, which can elicit systemic inflammation and increase the risk of chronic diseases. Conclusions: This narrative review highlights the potential applications of CrM for related tactical occupations, with a particular focus on firefighters, and calls for further research into these populations.
180: Appropriate utilization of chest x-ray imaging on extracorporeal membrane oxygenation (ECMO) patients
Barr, Jo’el, Zimmerman, Jill, Hannon, Rachel, Matos, Nikki , Nichols, Mick D., White, Andrew, Guru, Pramod , Chaudhary, Sanjay

Mayo Clinic

ASAIO Journal | September 28, 2024 | Volume: 70 | Issue: Supplement 4 | Pages: 112-112

10.1097/01.mat.0001070520.69015.94 Get It

Spinal Anesthesia for Multilevel Awake Minimally Invasive Transforaminal Lumbar Interbody Fusion: Single-Center Experience
Llano, Juan P Navarro-Garcia de , Cueto, Macarena Fuentes-Fernandez, Sánchez-Garavito, Jesús E. , Shah, Siddharth , Iyer, Harshvandan, Ariwodo, Ogechuku, Michaelides, Loizos , Patterson, Jennifer S., White, Kate E., Bojaxhi, Elird , Navarro-Ramírez, Rodrigo , Buchanan, Ian A. , Iyer, Harshvardhan , Navarro-Garcia de Llano, Juan P, Fuentes-Fernandez Cueto, Macarena, Roberts, Andrew P, Iyer, Harshvardhan G , Roberts, Andrew P., Biase, Gaetano De , ReFaey, Karim , Abode-Iyamah, Kingsley

Mayo Clinic

Operative Neurosurgery | September 27, 2024 | Volume: 28 | Issue: 6 | Pages: 855-861

10.1227/ons.0000000000001380 | PMID 39329514 Get It

BACKGROUND AND OBJECTIVES: Awake minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) generates minimal surrounding tissue damage and has been shown to be a safe, time-effective, and cost-reductive technique in single-level procedures. The purpose of this study was to advocate for the utilization of multilevel MIS-TLIF even in challenging cases as it has demonstrated positive outcomes. METHODS: Chart review was conducted for consecutive patients undergoing awake multilevel MIS-TLIF from 2020 to 2023. Various demographic, preoperative, and postoperative variables were collected and descriptively analyzed. RESULTS: Sixteen patients underwent multilevel awake MIS-TLIF at our institution during the specified period. Among them, 87.5% underwent a two-level procedure and 12.5% a three-level procedure. The median age ± IQR was 69.5 ± 11 years, with a slight male predominance (56.25%). Common comorbidities included hypertension (56.25%), obesity (37.5%), sleep apnea (25%), and type 2 diabetes (18.75%). The American Society of Anesthesiologists risk was 2 in 43.75% of patients and 3 in 56.25%. All patients presented pain, and 12.5% showed motor deficit. Intraoperative data showed a median of 196 minutes in the operating room where 156 ± 27.75 minutes corresponded to actual procedure time. The median estimated blood loss was 50 ± 70 cc. In the immediate postoperative period, 1 patient had nausea and emesis, and 1 reported fatigue. The median pain score during this period was 4.6 ± 2.03. Pain control medications were required for various patients, with methocarbamol (50%), hydromorphone (37.5%), and oxycodone (25%) being the most commonly prescribed in the postanesthesia care unit. No patient had new neurological deficits after the surgical intervention. The median length of stay was 2 days ±1.25. All patients were discharged with no complications. CONCLUSION: Multilevel awake MIS-TLIF emerges as a safe and effective technique for complex cases, enhancing patient quality of life with minimal blood loss and postoperative pain.